Arcturus Therapeutics posts press release on Thermo Fisher collaboration for ARCT-032 cystic fibrosis program

Thermo Fisher Scientific Inc.
Arcturus Therapeutics

Thermo Fisher Scientific Inc.

TMO

0.00

Arcturus Therapeutics

ARCT

0.00
  • Arcturus posted a press release on a strategic collaboration with Thermo Fisher to support Phase 3 development of ARCT-032 in cystic fibrosis.
  • Thermo Fisher will provide Phase 3 manufacturing services; Arcturus expects to run Phase 3 trials through Thermo Fisher’s PPD unit if Phase 2 is positive.
  • Thermo Fisher would receive exclusive commercial manufacturing rights under a separate agreement, contingent on regulatory approval of ARCT-032.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief on July 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.